James Moy to Prospective Studies
This is a "connection" page, showing publications James Moy has written about Prospective Studies.
Connection Strength
0.190
-
Efficacy and Safety of Human Intravenous Immunoglobulin 10% (Panzyga?) in Patients with Primary Immunodeficiency Diseases: a Two-Stage, Multicenter, Prospective, Open-Label Study. J Clin Immunol. 2017 Aug; 37(6):603-612.
Score: 0.106
-
Step-Up Therapy in Black Children and Adults with Poorly Controlled Asthma. N Engl J Med. 2019 09 26; 381(13):1227-1239.
Score: 0.031
-
Intravenous immunoglobulin 10% in children with primary immunodeficiency diseases. Immunotherapy. 2018 10; 10(14):1193-1202.
Score: 0.028
-
Acetaminophen versus Ibuprofen in Young Children with Mild Persistent Asthma. N Engl J Med. 2016 Aug 18; 375(7):619-30.
Score: 0.025